Found 4 matching records:
HXB2 Location | Gag(76-86) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
RSLYNTVATLY
|
Epitope Alignment | ||||||||||||||||||||||||||||||||||||||||||||||
Variants |
|
|||||||||||||||||||||||||||||||||||||||||||||||
Epitope Name | RY11 | |||||||||||||||||||||||||||||||||||||||||||||||
Species (MHC/HLA) | human(A*02:01, A*30:02) |
Showing all: 15 variant(s).
Variant ID. | 2973 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLYNTiATLY |
Mutations | V/I |
Epitope Location | V7I |
HXB2 Location | V82I |
Mutation Type | DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLYNTiATLY had a large increase in binding to HLA-A*02 in vitro, but it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate V82I mutation-containing peptides to be escapes. |
Variant ID. | 2974 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLYNTVAvLY |
Mutations | T/V |
Epitope Location | T9V |
HXB2 Location | T84V |
Mutation Type | DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLYNTVAvLY bound at the same Kd to HLA-A*02 as to the WT sequence, but EliSpot response in 2/3 chronically-infected, untreated patients was abolished. Slightly diminished response was seen in one patient. The authors designate T84V mutation-containing peptides as escapes. |
Variant ID. | 2975 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLYNTiAvLY |
Mutations | V/I T/V |
Epitope Location | V7I T9V |
HXB2 Location | V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLYNTiAvLY did not bind to HLA-A*02 in vitro, and it showed complete abrogation of ex-vivo EliSpot responses in 1/3 chronically-infected, untreated patients; diminished response in another patient; and no change in the third as compared to WT RY11. The authors designate both V82I and T84V mutation-containing peptides to be escapes. |
Variant ID. | 2976 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLfNTiATLY |
Mutations | Y/F V/I |
Epitope Location | Y4F V7I |
HXB2 Location | Y79F V82I |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLfNTiATLY did not bind to HLA-A*02, and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients, with no changes in 1 patient as compared to WT RY11. The authors designate Y79F or V82I mutation-containing peptides as escapes. |
Variant ID. | 2977 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLfNTVATLY |
Mutations | Y/F |
Epitope Location | Y4F |
HXB2 Location | Y79F |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLfNTVATLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate Y79F mutation-containing peptides to be escapes. |
Variant ID. | 2978 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLfNTVAvLY |
Mutations | Y/F T/V |
Epitope Location | Y4F T9V |
HXB2 Location | Y79F T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLfNTVAvLY did not bind to HLA-A*02 in vitro, and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL response in another such patient; with no changes in the third patient when compared to wt RY11. The authors designate Y79F and T84V mutation-containing peptides to be escapes. |
Variant ID. | 2979 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | RSLfNTiAvLY |
Mutations | Y/F V/I T/V |
Epitope Location | Y4F V7I T9V |
HXB2 Location | Y79F V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant RSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients; with abrogation of CTL response in 1 other patient; and a slight increase for the last patient as compared with WT RY11. The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes. |
Variant ID. | 2980 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLYNTVATLY |
Mutations | R/K |
Epitope Location | R1K |
HXB2 Location | R76K |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLfNTiATLY did not bind to HLA-A*02 in vitro, but it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to WT RY11. |
Variant ID. | 2981 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLYNTVAvLY |
Mutations | R/K T/V |
Epitope Location | R1K T9V |
HXB2 Location | R76K T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLYNTVAvLY had loss of binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient, and abrogation of CTL responses in the other 2. |
Variant ID. | 2982 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLYNTiATLY |
Mutations | R/K V/I |
Epitope Location | R1K V7I |
HXB2 Location | R76K V82I |
Mutation Type | DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLYNTiATLY had an increase in binding to HLA-A*02 in vitro; but it showed a significant decrease in EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL responses in the second patient; and no change in the third when compared to wt RY11. The authors designate V82I mutation-containing peptides to be escapes. |
Variant ID. | 2983 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLYNTiAvLY |
Mutations | R/K V/I T/V |
Epitope Location | R1K V7I T9V |
HXB2 Location | R76K V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLYNTiAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients and abrogation of CTL response in the third. The authors designate V82I or T84V mutation-containing peptides as escapes. |
Variant ID. | 2984 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLfNTVATLY |
Mutations | R/K Y/F |
Epitope Location | R1K Y4F |
HXB2 Location | R76K Y79F |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLfNTVATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 3/3 chronically-infected, untreated patients. The authors designate Y79F mutation-containing peptides as escapes. |
Variant ID. | 2985 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLfNTiATLY |
Mutations | R/K Y/F V/I |
Epitope Location | R1K Y4F V7I |
HXB2 Location | R76K Y79F V82I |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLfNTiATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate Y79F or V82I mutation-containing peptides as escapes. |
Variant ID. | 2986 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLfNTVAvLY |
Mutations | R/K Y/F T/V |
Epitope Location | R1K Y4F T9V |
HXB2 Location | R76K Y79F T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLfNTVAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in EliSpot response in 2 chronically-infected, untreated patients; and abrogation of CTL response in the third. The authors designate Y79F or T84V mutation-containing peptides as escapes. |
Variant ID. | 2987 |
---|---|
Epitope Seq. | RSLYNTVATLY |
Variant Seq. | kSLfNTiAvLY |
Mutations | R/K Y/F V/I T/V |
Epitope Location | R1K Y4F V7I T9V |
HXB2 Location | R76K Y79F V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant kSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients, with abrogation of CTL response in the other 2 patients as compared to WT RY11. The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes. |
Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.
HXB2 Location | Gag(77-85) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
SLYNTVATL
|
Epitope Alignment | ||||||||||||||||||||||||||||
Variants |
|
|||||||||||||||||||||||||||||
Epitope Name | SL9 | |||||||||||||||||||||||||||||
Species (MHC/HLA) | human(A*02:01) |
Showing all: 9 variant(s).
Variant ID. | 2963 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTVAvL |
Mutations | T/V |
Epitope Location | T9V |
HXB2 Location | T85V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper LE: literature escape SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding, Sequence |
Note | CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTVAvL, reversion to SL9 is predicted to result from selection for optimal viral growth. This variant did not bind HLA-A*02 in vitro; and could not elicit response in 2/3 chronically-infected, untreated patients, but showed a complete EliSpot response in the other patient when compared to that elicited by wt peptide SL9. The authors designate all T84V-mutation containing peptides to be escapes. |
Variant ID. | 2965 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLfNTVAvL |
Mutations | -/K Y/F T/V |
Epitope Location | -1K Y4F T9V |
HXB2 Location | -77K Y80F T85V |
Mutation Type | LE: literature escape |
Epitope Subtype | B |
Variant Subtype | B |
Method | Sequence |
Note | CTL selection at TCR contact residues is predicted to drive {k}SLYNTVAvL (SL9-V) to {k}SLfNTVAvL (SL9-KFV); reversion to SL9-V is predicted to result from selection for optimal viral growth. |
Variant ID. | 2966 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLfNTiAvL |
Mutations | -/K Y/F V/I T/V |
Epitope Location | -1K Y4F V7I T9V |
HXB2 Location | -77K Y80F V83I T85V |
Mutation Type | LE: literature escape |
Epitope Subtype | B |
Variant Subtype | B |
Method | Sequence |
Note | CTL selection at TCR contact residues is predicted to drive {k}SLfNTVAvL (SL9-KFV) or {k}SLfNTiATL(SL9-KFI) or {R}SLFNTiAvL(SL9-IV) to {k}SLfNTiAvL (SL9-KFIV), reversion to SL9-KFV is predicted to result from selection for optimal viral growth. |
Variant ID. | 2967 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLYNTVATL |
Mutations | -/K |
Epitope Location | -1K |
HXB2 Location | -77K |
Mutation Type | LE: literature escape |
Epitope Subtype | B |
Variant Subtype | B |
Method | Sequence |
Note | Epitope {R}SLYNTVATL is seen to vary to {k}SLYNTVATL (SL9-K). |
Variant ID. | 2968 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLfNTVATL |
Mutations | Y/F |
Epitope Location | Y3F |
HXB2 Location | Y79F |
Mutation Type | E: escape documented in this paper LE: literature escape SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding, Longitudinal study |
Note | CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLfNTVATL (SL9-F); reversion to SL9 is predicted to result from selection for optimal viral growth. This variant showed a slight increase in EliSpot responses in 2/3 chronically-infected, untreated patients when compared to SL9. |
Variant ID. | 2969 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLfNTiATL |
Mutations | -/K Y/F V/I |
Epitope Location | -1K Y4F V7I |
HXB2 Location | -77K Y80F V83I |
Mutation Type | LE: literature escape |
Epitope Subtype | B |
Variant Subtype | B |
Method | Sequence |
Note | CTL selection at TCR contact residues is predicted to drive SL9-KF {k}SLfNTVATL to {k}SLfNTiATL (SL9-KFI), reversion to SL9-KF is predicted to result from selection for optimal viral growth. |
Variant ID. | 2970 |
---|---|
Epitope Seq. | {R}SLYNTVATL |
Variant Seq. | {k}SLfNTVATL |
Mutations | -/K Y/F |
Epitope Location | -1K Y4F |
HXB2 Location | -77K Y80F |
Mutation Type | LE: literature escape |
Epitope Subtype | B |
Variant Subtype | B |
Method | Sequence |
Note | CTL selection at TCR contact residues is predicted to drive epitope {k}SLYNTVATL (SL9) to variant, {k}SLfNTVATL (SL9-KF). |
Variant ID. | 2971 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTiATL |
Mutations | V/I |
Epitope Location | V6I |
HXB2 Location | V82I |
Mutation Type | DHB: diminished HLA binding or increased off-rate DR: diminished response E: escape documented in this paper LE: literature escape SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding, Sequence |
Note | CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTiATL (SL9-I); reversion to SL9 is predicted to result from selection for optimal viral growth. This variant shows a loss of binding to HLA-A*02 in vitro; and is unable to generate a CTL response in 1 chronically-infected, untreated patient, with slight decrease in EliSpot in 2 others as compared to wt peptide SL9. The authors refer to all V82I mutation-containing peptides as escapes. |
Variant ID. | 2972 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLYNTiAvL |
Mutations | V/I T/V |
Epitope Location | V6I T8V |
HXB2 Location | V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper LE: literature escape SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding, Sequence |
Note | CTL selection at TCR contact residues is predicted to drive SL9-I (SLYNTiATL) to SLYNTiAvL (SL9-IV); reversion to SL9-I is predicted to result from selection for optimal viral growth. This variant could not bind HLA-A*02 in vitro; and did not elicit EliSpot responses in 2/3 chronically-infected, untreated patients, but it showed an increased CTL response in the third patient as compared to WT SL9. The authors designate all V82I and T84V mutation-containing peptides as escapes. |
Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.
HXB2 Location | Gag(77-86) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
SLYNTVATLY
|
Epitope Alignment | ||||||||||||||||||||||
Variants |
|
|||||||||||||||||||||||
Epitope Name | SY10 | |||||||||||||||||||||||
Species (MHC/HLA) | human(A*02) |
Showing all: 7 variant(s).
Variant ID. | 2988 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLYNTVAvLY |
Mutations | T/V |
Epitope Location | T8V |
HXB2 Location | T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLYNTVAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all T84V mutation-containing peptides as escapes. |
Variant ID. | 2989 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLYNTiATLY |
Mutations | V/I |
Epitope Location | V6I |
HXB2 Location | V82I |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLYNTiATLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all V82I mutation-containing peptides as escapes. |
Variant ID. | 2990 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLYNTiAvLY |
Mutations | V/I T/V |
Epitope Location | V6I T8V |
HXB2 Location | V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLYNTiAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all V82I and T84V mutation-containing peptides as escapes. |
Variant ID. | 2991 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLfNTVATLY |
Mutations | Y/F |
Epitope Location | Y3F |
HXB2 Location | Y79F |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLfNTVATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes. |
Variant ID. | 2992 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLfNTiAvLY |
Mutations | Y/F V/I T/V |
Epitope Location | Y3F V6I T8V |
HXB2 Location | Y79F V82I T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLfNTiAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F, V82I and T84V mutation-containing peptides as escapes. |
Variant ID. | 2993 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLfNTVAvLY |
Mutations | Y/F T/V |
Epitope Location | Y3F T8V |
HXB2 Location | Y79F T84V |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLfNTVAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes. |
Variant ID. | 2994 |
---|---|
Epitope Seq. | SLYNTVATLY |
Variant Seq. | SLfNTiATLY |
Mutations | Y/F V/I |
Epitope Location | Y3F V6I |
HXB2 Location | Y79F V82I |
Mutation Type | DHB: diminished HLA binding or increased off-rate E: escape documented in this paper SF: susceptible form |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant SLfNTiATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes. |
Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.
HXB2 Location | Gag(82-91) | Gag Epitope Map
View variants at this location |
||||
---|---|---|---|---|---|---|
Epitope |
IAVLYCVHQR
|
Epitope Alignment | ||||
Variants |
|
|||||
Epitope Name | IR10 | |||||
Species (MHC/HLA) | (A*11) |
Showing all: 1 variant(s).
Variant ID. | 2964 |
---|---|
Epitope Seq. | IAVLYCVHQR |
Variant Seq. | IvVLYCVHQR |
Mutations | A/V |
Epitope Location | A2V |
HXB2 Location | A83V |
Mutation Type | OV: observed variant |
Epitope Subtype | B |
Variant Subtype | B |
Method | CD8 T-cell Elispot - IFNy, HLA binding |
Note | Variant A11-VR10, IvVLYCVHQR, may also be present and is restricted by the same HLA, A*11. |
Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.
This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.